United StatesThe article begins with the author expressing suspicions about why legacy media outlets do not adequately cover Big Pharma. The piece suggests there may be underlying reasons related to industry influence, lack of transparency, or conflicts of interest that prevent comprehensive and unbiased reporting on pharmaceutical companies. While the author raises concerns about media bias and corporate accountability, the text does not provide specific evidence or detailed arguments to support these claims.
Bias read (Progressive): The article implies that legacy media has a biased stance toward Big Pharma, suggesting a potential conflict between media interests and pharmaceutical industry influence. This framing leans left by highlighting systemic issues within traditional media and questioning their objectivity, rather than報
